- Home
- Past Conferences
- Drug Discovery Re-Invented
Drug Discovery Re-Invented
Emerging Role of Biotechs, Academics and Non-Profits
16 Oct - 19 Oct 2013
Scottsdale, Arizona, USA
Early Bird - Expired • Talk Submission - Expired • Poster Submission - Expired • Registration & Payment Deadline - Expired
Synopsis
The Drug Discovery Re-Invented Fusion conference will center on new approaches to drug discovery in an industry where the landscape is changing rapidly. With large pharma reducing investment in internal early stage research, drug pipelines will increasingly be filled by alternative sources. These players include: government, academic labs, non-profits, biotech companies, and pharmaceutical “open innovation” models. The conference will also provide examples of successful strategies for advancing new drug candidates in this era of distributed discovery.
Key Sessions include:
- Discovery Re-Invented
- Novel Pharma Approaches
- Collaborative Drug Discovery
- Natural Products
- Structure, Modelling and Informatics
- Biologics and Non-traditional Therapeutics
- Discovery Technologies
- Exhibit
Dr. William A. Kinney's Bio:
Dr. Kinney began his industrial career in the CNS group at Wyeth, where he invented the cyclobutenedione-containing NMDA antagonist perzinfotel that progressed to phase II clinical trials for pain. At Magainin Pharmaceuticals, he directed projects on trodusquemine (phase II, obesity) and squalamine (phase II, eye disease), two shark-derived natural products. In 2000, he joined Johnson & Johnson, where he pursued peptide-mimetic integrin antagonists and urotensin-II receptor modulators for cardiovascular indications. He also made seminal discoveries with respect to self-assembling collagen-mimetic peptides that stimulate platelet aggregation. Currently, Dr. Kinney is a faculty member within the Institute for Hepatitis and Virus Research. He directed the technical feasibility, business plan development, and logistics for the donation of the former Merck Research Laboratories Natural Product Collection to the IHVR. He also initiated a structure based drug design project on a new anti-viral target in collaboration with Prof. Peter Katsikis at Drexel University to develop PI3K p110d kinase inhibitors that block host cell signaling pathways required for influenza infection and pathogenesis. He is an adjunct faculty member atDrexelUniversityand Founder of IteraMed, a company focused on internal and out-sourced organic synthesis, consulting, and drug discovery. His scientific contributions include 70 publications, invited lectures, and oral presentations and inventorship on 37 issued U.S. patents.
Dr. Charles H. Reynolds' Bio:
Dr. Reynolds is currently President of GFree, LLC, a structure-based drug discovery company based in suburban Philadelphia. He is an expert in the areas of computational chemistry, structure-based design, and drug discovery with more than 25 years of experience. Dr. Reynolds is also a Director on the Advisory Board of Quantum Bio, Inc. and an adjunct professor at the Pennsylvania Drug Discovery Institute. Previously he was Senior Director and Head of Discovery Technologies at Ansaris, where he was a member of the executive leadership team and responsible for the company’s proprietary fragment-based design technology platform. Prior to joining Ansaris, he led modeling groups at the Springhouse, PA and La Jolla, CA research sites of Johnson & Johnson, where he and his team made significant contributions to discovery programs in neuroscience, oncology, pain, and cardiovascular disease. Dr. Reynolds began his career at Rohm and Haas (now Dow) where his scientific accomplishments were recognized with the company’s highest science award, the Otto Haas Award. He has held a variety of leadership positions in the American Chemical Society (ACS), and was recently named a Fellow of the ACS. Some of his other awards include The Standards of Leadership Award (J&J) and Excellence in Science Award (J&J).
Dr. Reynolds earned a BA, with honors, from Austin College and PhD from the University of Texas at Austin. He was an adjunct professor at the University of Pennsylvania and has supervised joint graduate and postdoctoral students at the Pennsylvania State University and the University of North Carolina at Chapel Hill. He has published approximately 100 papers, patents, and book chapters, and is a co-editor of two books. His comments on drug discovery have been sought by news organizations ranging from C&E News to the Wall Street Journal.
Confirmed Speakers
Plenary Speakers
Steven Young
Consultant, Retired VP Merck & Co.
Michael Foley
Director, Chemical Biology, Novel Therapeutics, Broad Institute
William Jorgensen
Sterling Professor, Yale University
Omar Vandal
Program Officer, Discovery & Translational Sciences, Bill & Melinda Gates Foundation
Sean Brady
Prof, Rockefeller University
David Lowe
CEO, Aeglea BioTherapeutics
Invited Speakers
James Barrow
Investigator, Lieber Institute
Jef De Brabander
Professor, UT Southwestern Medical Center
Benjamin Blass
Assistant Professor, Temple University School of Pharmacy, Moulder Center for Drug Discovery Research
Michael Trzoss
Principal Scientist II, Trius Therapeutics
Joseph Vacca
Owner, J. Vacca Consulting LLC
Craig Thomas
Chemistry Technologies Group Leader, NCATS
David Gorenstein
Assoc. Dean Research, Medical School, University of Texas HSC Houston
Michael Goetz
Director, NPDI, NPDI-IHVR
Leah Frye
Vice President, Schrodinger
Zhengying Pan
Research Fellow, Peking University, Shenzhen Graduate School
James Breitenbucher
Director of Chemistry, Dart Neuroscience
Bart DeCorte
VP Business Development, Mercachem
Kenneth Merz
Director, Institute for Cyber Enabled Research (iCER) and Joseph Zichis Chair in Chemistry , Michigan State University
Aaron Sato
VP Research, Sutro Biopharma
Todd Chappell
Entrepreneur-in-Residence, BioHealth Innovation, Inc.
Sandhya Kortagere
Assistant Professor, Drexel University College of Medicine
Andreas Bader
Director - Research, Mirna Therapeutics
Patrick Lam
Drexel University College of Medicine, Former BMS Chemistry Director
Janet Ralbovsky
Licensing Associate , University of Tennessee Research Foundation
Serge Boulet
Senior Research Scientist, Eli Lilly and Company
Mark McDonnell
Senior Scientist, Fox Chase Chemical Diversity Center Inc.
Paul Leeson
Consultant, GlaxoSmithKline
Matthew Segall
CEO, Optibrium Ltd.
Guy Carter
Chief Scientific Officer, Biosortia Pharmaceuticals
Chris Williams
Principal Scientist , Chemical Computing Group
Gabor Butora
Principal Scientist, Merck & Co.
Barry Bunin
CEO, Collaborative Drug Discovery
Phillip Cox
Chief Scientist, Noramco Inc
Kristopher Josephson
Director, Ra Pharmaceuticals
Programme
Wednesday, October 16, 2013 |
||
|
15:30 – 17:00 |
Registration & Reception |
|
|
17:00 – 17:15 |
Opening Comments |
|
|
Discovery Re-Invented |
||
|
17:15 – 18:00 |
Steve Young |
HIV Integrase Inhibitors: The Chemistry Behind The Discovery of Isentress |
|
18:00 – 18:30 |
James Breitenbucher |
Drug Discovery – What really needs to be “Re-Invented”? |
|
18:30 – 19:00 |
Bart DeCorte |
The Janssen Incubator – A Novel Business Model to Spark Internal Innovation |
|
19:00 - 20:00 |
Welcome Reception/Dinner |
|
|
Novel Pharma Approaches |
||
|
20:00 – 20:30 |
Patrick Lam |
Discovery of Eliquis®/Apixaban, a novel FXa anticoagulant |
|
20:30 – 21:00 |
Serge Boulet |
Phenotypic Drug Discovery of Novel Anti-Angiogenics |
|
21:00 – 21:30 |
Gabor Butora |
Chemically Modified Oligonucleotides for RNAi |
|
21:30 -22:00 |
Michael Trzoss |
Novel GyrB/ParE Inhibitors |
|
|
Free Time |
|
Thursday, October 17, 2013 |
||
|
06:00 – 08:00 |
Breakfast |
|
|
Collaborative Drug Discovery I |
||
|
08:00 – 08:45 |
Michael Foley |
TBA |
|
08:45 – 09:15 |
Craig Thomas |
Associative Data Profiles Connect Basic Research to Translational Efforts |
|
09:15 – 09:45 |
Todd Chappell |
Entrepreneurs-in-Residence, Not Just for Venture Capitalists |
|
09:45 – 10:15 |
James Barrow |
Genetics-Driven Psychiatry Drug Discovery |
|
10:15 – 10:30 |
Greg Miknis |
Promoting Colorado Drug Discovery Research: Creation of the Colorado Center for Drug Discovery (C2D2) |
|
10:30 – 11:00 |
Refreshments |
|
|
11:00 – 11:30 |
Joseph Vacca |
"Drug Discovery in the 21st Century" |
|
11:30 – 12:00 |
Zhengying Pan |
Discovery of Selective Irreversible Inhibitors for Bruton’s Tyrosine Kinase |
|
12:00 – 12:15 |
Barry Bunin |
Collaborative Drug Discovery Technology Neglected, Infectious, CNS, and Repositioning Applications |
|
12:15 – 12:30 |
Olanrewaju Omobuwajo |
Fertility reducing effect of pandanus candelabrum p.beauv. Leaves in male wistar rats |
|
12:30 – 13:15 |
Group Lunch |
|
|
12:30 – 16:30 |
Free Time |
|
|
Natural Products |
||
|
16:30 – 16:45 |
Michael Goetz |
The Natural Products Discovery Institute. Classical and novel approaches to drug discovery |
|
16:45 – 17:30 |
Sean Brady |
Watch where you step, there is new chemistry everywhere |
|
17:30 – 18:00 |
Jef De Brabander |
Opportunities for Lead Discovery in a Biomedical Research Environment |
|
18:00 – 18:20 |
Guy Carter Biosortia Pharmaceuticals |
A deep dive into aquatic microbial consortia for drug discovery |
|
18:20 – 18:40 |
Jetze Tepe
|
Non-competitive regulation of the human proteasome by natural products and natural product inspired scaffolds |
|
18:40 – 19:00 |
Phillip Cox Noramco |
Development of poppy varieties to suit changing market requirements |
|
19:00 – 20:00 |
Group Dinner |
|
|
20:00 – 22:00 |
Poster Session & Cocktail Reception |
|
Friday, October 18, 2013 |
||
|
06:00 – 08:00 |
Breakfast & Free Morning |
|
|
12:00 – 12:45 |
Group Lunch |
|
|
Structure, Modeling and Informatics |
||
|
12:45 13:30 |
William Jorgensen |
Drug Discovery Accelerated by Computational Methods |
|
13:30 – 14:00 |
Kenneth Merz |
Blurring to Bring Binding Free Energies into Focus |
|
14:00 – 14:30 |
Chris Williams |
Water Placement - Application of 3D-RISM to structure-based drug design |
|
14:30 – 14:45 |
Christopher Reynolds |
Unravelling similarities between class A and class B GPCRs through modelling and mutagenesis |
|
14:45 – 15:00 |
Lance Westerhoff |
Quantum mechanics-based macromolecular x-ray refinement as an advanced method for the high throughput crystallography |
|
15:00 – 15:30 |
Leah Frye |
Nimbus and Schrödinger Reinventing Drug Discovery: Rapid and Efficient Development of Acetyl-CoA Carboxylase Inhibitors |
|
15:30 – 16:00 |
Paul Leeson |
Compound Quality: What Have We Learned? |
|
16:00 - 16:30 |
Refreshments |
|
|
Biologics and Non-traditional Therapeutics |
||
|
16:30 – 17:15 |
David Lowe |
Targeting the Amino Acid Dependence of Cancer |
|
17:15 – 17:45 |
Andreas Bader |
MRX34 – from bench to bedside |
|
17:45 – 18:15 |
David Gorenstein |
Next Generation X-Aptamers for Personalized Nanomedicine |
|
18:15 – 18:45 |
Aaron Sato |
Rapid Design and Production of Homogeneous Best-in-Class Protein Therapeutics using Cell-Free Protein Expression |
|
18:45 – 19:00 |
Ian Pottie Mount Saint Vincent University |
Developing an Imaging Agent for Cholinesterase Enzymes to Diagnose Alzheimer’s Disease |
|
19:00 – 19:30 |
Refreshments |
|
|
Foundation Support for Neglected Diseases |
||
|
19:30 – 20:15 |
Omar Vandal |
Partnerships in Drug Discovery and Technology Development for Diseases of the Developing World |
|
20:30 – 00:00 |
*Gala Night, Group Photo & Poster Awards* |
|
Saturday, October 19, 2013 |
||
|
07:00 – 09:00 |
Breakfast |
|
|
09:00 |
Chair Opening |
|
|
Discovery Technologies |
||
|
09:00 – 09:20 |
Dietmar Wolf AnalytiCon |
Novel Macrocyclic Libraries Evolved from Natural Product Technology Platforms |
|
09:20 – 09:40 |
Prem Premsrirut |
RNAi mouse models: Revolutionizing drug discovery in vivo |
|
09:40 – 10:00 |
Philip Jones |
Institute for Applied Cancer Science, developing the next generation of oncology agents for targeted patient populations |
|
10:00 – 10:30 |
Matthew Segall |
Finding and Applying Rules for Successful Drug Discovery |
|
10:30 – 11:00 |
Refreshments |
|
|
11:00 – 11:30 |
Janet Ralbovsky |
Technology Transfer Re-invented: How is Academia Adapting to the Changes in Drug Discovery? |
|
11:30 – 12:00 |
Joel Dudley Mount Sinai School of Medicine |
Developing a Systematic Computational Approach to Identify Novel Drug Indication Relationships Using Public Gene Expression Profiles |
|
12:00 – 12:45 |
Group Lunch |
|
|
Collaborative Drug Discovery II |
||
|
12:45 – 13:15 |
Benjamin Blass |
Drug Discovery in the Academic Community |
|
13:15 – 13:45 |
Mark McDonnell |
Riluzole prodrugs for melanoma and ALS |
|
13:45 – 14:15 |
Sandhya Kortagere |
Designing protein-protein interaction inhibitors as novel antimalarial chemotherapeutics |
|
14:15 – 14:30 |
Peter Cheuka |
Synthesis of aminomethylthiazole analogues for evaluation as antiplasmodial agents |
|
14:30 – 15:00 |
Kris Josephson |
Discovery of Potent Macrocyclic Peptides for Drug Development |
|
15:00 – 15:15 |
Closing Remarks (Chairs & Fusion) |
|
|
15:15 |
Departures |
|
Supported by
Venue & Location
Hilton Scottsdale Resort & Villas
Laze in the Arizona sun at the Hilton Scottsdale Resort & Villas, an AAA Four Diamond resort set at the foot of the Camelback Mountain. This beautiful property located in the heart of Scottsdale is inspired by the Sonoran Desert with an elegant and luxurious interiour.
Delegates will enjoy an arranged feast for breakfast, lunch and dinner throughout the conference period. During each meal delegates are entitled to unlimited sodas and one house wine or beer during dinner. The themed Gala Night, ‘A Night Under the Stars', takes place on the third evening of the conference with a mouth-watering feast exclusively designed by the head chef, an open bar and a live band. We welcome all delegates and their accompanying persons to the Gala Night – a truly fun filled night not to be missed!
Hotel Facilities
- Resort Swimming Pool
- Gym & Spa
- Complimentary WI-FI in guestrooms and conference areas
The Hilton Scottsdale Resort and Villas has received the 2012 Trip Advisor Certificate of Excellence Award.
The majestic Grand Canyon, one of the Seven Natural Wonders of the World, is an extremely popular attraction for this conference. We will be working closely with a reputable tour operator who will be arranging day trips to the Grand Canyon before and after the conference whether it be an individual or group booking. We recommend additional nights are booked well in advance if you plan to book this day trip to avoid disappointment. For further information on the Grand Canyon Tour, please contact us.
General Information
Venue Rating
★ ★ ★ ★
Currency
US Dollar (USD)
Address
Nearest Airport
Phoenix Sky Harbor International Airport
Location
Arizona is the sixth largest state in the United States surrounded by truly breath taking views of mountains, valleys, high plateaus, narrow canyons and colourful stretches of the desert. The constant warm arid temperatures and clear starry night skies add to the beauty of this wonderful location. Arizona is home to the majestic Grand Canyon, one of the Seven Natural Wonders of the World. This famous and inspiring landmark can be incorporated into day trip as an extension of the conference allowing our delegates to experience an unforgettable adventure!
Scottsdale is a city of extraordinary treasures with an old western charm and Native American culture, all just steps away from the Sonoran Desert’s rugged beauty. Home to more than 200 outstanding golf courses designed by some of the greatest names in golf, the McDowell Sonoran Preserve, fabulous one-off boutiques, fine art galleries, world-class museums, innovative architecture and acclaimed restaurants, there is definitely something for everyone.
Gallery
View on Flickr
If you are interested in this meeting but not yet ready to register, you can sign up for updates here and our team will keep you updated regarding deadline reminders and grant opportunities relating to this meeting only.
Bronze Sponsors
Exhibitors
Media Partners
If you're interested in sponsoring this conference please contact us.
Conference Manager
Laura Trundle
Need some help? Chat to the Fusion team today
As a family run business, our dedication runs deep. We’re committed to each other and, even more so, to every attendee’s experience, delivering a level of care and passion that’s truly unmatched.
